Key facts
- GSK beat second-quarter profit expectations.
- The company launched a £1.9 billion ($2.52 billion) cost savings drive.
- GSK reported 2025 sales of £32.7 billion, up 4% year-over-year.
- Specialty Medicines sales grew 17% to £13.5 billion in 2025.
- GSK expects 2026 turnover growth between 3% and 5%.
GSK announced on Tuesday that it surpassed second-quarter profit expectations and initiated a £1.9 billion ($2.52 billion) cost savings program. The British pharmaceutical company aims to enhance its development pipeline to achieve its long-term sales targets.
For the full year 2025, GSK reported total sales of £32.7 billion, a 4% increase on a reported basis and 7% on a constant exchange rate basis. Specialty Medicines sales grew 17% to £13.5 billion, driven by strong performance in Respiratory, Immunology & Inflammation, Oncology, and HIV segments. Vaccines sales reached £9.2 billion, with notable contributions from Shingrix and Arexvy. General Medicines sales were £10.0 billion.
The company generated £8.9 billion in cash from operations and £4.0 billion in free cash flow in 2025. GSK also reaffirmed its financial outlook, expecting 2026 turnover growth between 3% and 5%, with core operating profit and core EPS growth projected at 7% to 9% each. The company has a £2 billion share buyback program, of which £1.4 billion has been executed to date, and declared a Q4 2025 dividend of 18 pence per share.